• Who we are
    • About GARDP
    • Strategy
      • 5 BY 25
    • Our Team
    • Partners
    • GARDP Worldwide
  • What we do
    • Antibiotic resistance response
    • Pandemic Preparedness
    • Research & Development
      • Discovery & Exploratory Research
      • Children’s antibiotics
      • Sexually transmitted infections
      • Serious bacterial infections
    • Access to Antibiotics
    • REVIVE: Education & Collaboration
    • SECURE: Expanding Sustainable Access to Antibiotics
  • News & resources
    • Press centre
    • Updates
    • Events
    • Stories
    • Viewpoints
    • Publications
    • 日本語資料
  • Take action
    • Learn about antibiotics
    • Become a partner
    • Donate
    • Work for GARDP
    • Request for Proposals
    • Contact us
  • Donate

Analysis of the clinical antibacterial and antituberculosis pipeline


15 Oct 2018

by Theuretzbacher U, Gottwalt S, Beyer P, Butler M, Czaplewski L, Lienhardt C, Moja L, Paul M, Paulin S, Rex JH, Silver LL, Spigelman M, Thwaites GE, Paccaud JP, Harbarth S. The Lancet Infectious Diseases, October 2018, doi: 10.1016/S1473-3099(18)30513-9.

Click here to read the article / PDF


More Scientific Articles

← Unavailability of old antibiotics threatens effective treatment for common bacterial infections
The Global Antibiotic Research and Development Partnership (GARDP): a not-for-profit antibiotic development organisation →

Programmes

Discovery & exploratory
Children’s antibiotics
Sexually transmitted infections
Serious bacterial infections
Access to Antibiotics

More GARDP sites

REVIVE: Education & Collaboration

Contact us

Contacts
Vacancies
Request for Proposals

Sign up to our newsletter to stay connected

Subscribe
  • Terms of use